Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway
Open Access
- 24 June 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305863
Abstract
The efficacy of rosuvastatin in reducing allergic inflammation has been established. However, its potential to reduce airway remodeling has yet to be explored. This study aimed to evaluate the efficacy of rosuvastatin in reducing airway inflammation and remodeling in a mouse model of chronic allergic asthma induced by sensitization and challenge with OVA. Histology of the lung tissue and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) showed a marked decrease in airway inflammation and remodeling in mice treated with rosuvastatin, as evidenced by a decrease in goblet cell hyperplasia, collagen deposition, and smooth muscle hypertrophy. Furthermore, levels of inflammatory cytokines, angiogenesis-related factors, and OVA-specific IgE in BALF, plasma, and serum were all reduced upon treatment with rosuvastatin. Western blotting was employed to detect AMPK expression, while immunohistochemistry staining was used to observe the expression of remodeling signaling proteins such as α-SMA, TGF-β, MMP-9, and p-AMPKα in the lungs. It was found that the activity of 5’-adenosine monophosphate-activated protein kinase alpha (AMPKα) was significantly lower in the lungs of OVA-induced asthmatic mice compared to Control mice. However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region. These results indicate that rosuvastatin can effectively reduce airway inflammation and remodeling in mice with chronic allergic asthma caused by OVA, likely due to the reactivation of AMPKα and a decrease in angiogenesis.Keywords
Funding Information
- National Natural Science Foundation of China (82060172)
- National Natural Science Foundation of China (81960547)
- National Natural Science Foundation of China (82260001)
- Natural Science Foundation of Hainan Province (ZDKJ202003)
- Natural Science Foundation of Hainan Province (ZDYF2020223)
This publication has 57 references indexed in Scilit:
- Statins and angiogenesis in non-cardiovascular diseasesDrug Discovery Today, 2022
- Rosuvastatin suppresses cytokine production and lung inflammation in asthmatic, hyperlipidemic and asthmatic-hyperlipidemic rat modelsCytokine, 2020
- Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECsEuropean Journal of Pharmacology, 2020
- Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized miceCytokine, 2019
- Pathological roles of the homeostatic chemokine CXCL12Cytokine & Growth Factor Reviews, 2018
- AMPK is activated early in cerebellar granule cells undergoing apoptosis and influences VADC1 phosphorylation status and activityApoptosis, 2017
- Airway remodeling in asthma: what really mattersCell and tissue research, 2017
- Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial armsAtherosclerosis, 2016
- Inhibition of AMP-Activated Protein Kinase Accentuates Lipopolysaccharide-Induced Lung Endothelial Barrier Dysfunction and Lung Injury in VivoThe American Journal of Pathology, 2013
- Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over TrialLipids, 2011